Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (NRIX) announced that the U.K. Medicines & Healthcare products Regulatory Agency granted Clinical Trial Authorization (CTA) for NX-5948, a selective degrader of Bruton’s tyrosine kinase (BTK). The Phase 1 trial for patients with relapsed B-cell malignancies is set to begin in early 2022. Preclinical studies revealed NX-5948’s effectiveness, showing significant tumor reduction and improved survival rates in models. Notably, it crossed the blood-brain barrier, positioning it for dual development in oncology and autoimmune diseases.

Nurix Therapeutics announced FDA clearance for its DeTIL-0255 Investigational New Drug Application, paving the way for a Phase 1 clinical trial expected to begin by year-end 2021. DeTIL-0255 is an autologous T cell therapy targeting advanced malignancies, particularly gynecological cancers. The trial aims to enroll up to 50 patients, focusing on recurrent or persistent cancers. This advancement follows the company's success with its oral CBL-B inhibitor, NX-1607, currently in Phase 1a trials.

Nurix Therapeutics (Nasdaq: NRIX) announced preclinical findings for its CBL-B inhibitor, NX-0255, that enhance T cell expansion and quality for tumor infiltrating lymphocyte (TIL) therapy. Results show DeTIL-0255, a drug-enhanced TIL candidate, generated significant increases in T cell expansion (p<0.001), reduced exhaustion markers (p<0.05), and improved cytotoxicity (p<0.001). The findings support advancing DeTIL-0255 into clinical trials, with plans for a Phase 1 trial targeting patients with gynecological tumors. Additionally, Michael T. Lotze, the company's CCO, received the 2021 SITC Lifetime Achievement Award.

Nurix Therapeutics (Nasdaq: NRIX) has announced that its CEO, Arthur T. Sands, M.D., Ph.D., will participate in two upcoming virtual healthcare conferences in November. The events include the Stifel 2021 Virtual Healthcare Conference on November 16, from 3:20 to 3:50 PM EST, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, from 11:30 to 11:55 AM EST. These discussions will be available via live webcast through the Investors section of the Nurix website, with archived copies accessible for 30 days following each event.

Nurix Therapeutics (NRIX) has reported initial data on its lead drug candidate, NX-2127, demonstrating over 90% degradation of Bruton’s tyrosine kinase (BTK) in patients with relapsed B-cell malignancies. This achievement marks a significant milestone in the targeted protein degradation approach for treating cancers. The phase 1a study reported promising results, with patients showing sustained BTK suppression and a notable partial response in a CLL patient resistant to traditional therapies. The company plans to advance to the expansion phase in 2022.

Nurix Therapeutics (NRIX) is set to present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1 dose-escalation trial of NX-2127 for treating relapsed or refractory B-cell malignancies at the 4th Annual Targeted Protein Degradation Summit. The presentation occurs on October 27, 2021, at 11:45 a.m. ET, led by CEO Arthur T. Sands. A conference call for further discussion will precede the presentation at 8:30 a.m. ET. NX-2127 is an orally bioavailable degrader of BTK, aimed at addressing treatment resistance in affected patients.

Nurix Therapeutics (Nasdaq: NRIX) announces participation in the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Key sessions include:

• Pre-Conference Workshop on TPD basics by Gwenn M. Hansen, Ph.D. on October 26 at 8:30 a.m. ET.
• Oral Session on clinical updates by CEO Arthur T. Sands, M.D., Ph.D. on October 27 at 11:45 a.m. ET.
• Panel Discussions on therapeutic applications and diversity led by Sands and Hansen on October 27 and 28.

This summit highlights Nurix's commitment to advancing targeted protein modulation for cancer treatment.

Nurix Therapeutics (NRIX) reported its Q3 2021 financial results, highlighting a strong cash position of $465.4 million as of August 31, 2021. The company initiated a Phase 1 trial for its lead E3 ligase inhibitor NX-1607, now with two drug candidates in clinical development. Collaboration revenue rose to $10.3 million, up from $4.1 million year-on-year, driven by collaborations with Sanofi and Gilead. However, R&D expenses increased to $30.9 million, resulting in a net loss of $28.8 million or ($0.65) per share, up from ($1.09) per share a year earlier.

Nurix Therapeutics (NRIX) announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021. Reinsdorf, former executive vice president and general counsel of Johnson Controls, brings extensive leadership experience, while Silva, former chief accounting officer at Vertex Pharmaceuticals, adds over 30 years of finance expertise. The company emphasizes that their expertise will aid in advancing multiple drug candidates into clinical trials by year-end 2021 as part of its innovative DELigase drug discovery platform.